You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    The ultimate goal of this Phase I application is to develop novel small moleculebroad spectrum therapeutics against viral infections caused by filoviruses that depend on the PPxY L domain motif for virus egress and spread of infectionEbolaEBOVand MarburgMARVviruses are highly pathogenic and classified as Category Ahigh priority bioterror pathogensAs there are no commercially available therapeutic ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate

    SBC: NeuroKine Therapeutics, LLC            Topic: NIA

    ABSTRACT Alzheimer s diseaseADand related dementias are increasing rapidly yetremarkablythere are no approved disease modifying drugsVirtually all trials targeting amyloid related pathways have failed over the lastyearsRegrettablyfew alternative targets or pathways have been exploredThereforethere is an urgent need to explore alternative pathways as monotherapies or as constituents of a multi drug ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Product for sensitive imaging of cells in vivo

    SBC: CELSENSE, INC.            Topic: NIBIB

    This project aims to develop and commercialize a novel and highly sensitive MRI probe technology for the cell therapy tools marketThis project will transfer technology invented in the academic lab of DrAhrens at UCSDto CelsenseIncan established company that offers imaging agents for visualizing the trafficking of cell therapies and inflammation in the body using magnetic resonance imagingMRIOveral ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Trigriluzole for the Treatment of Cocaine Addiction

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIDA

    We have discovered trigriluzoleTRLZa tripeptide prodrug improved version of the market drug riluzoleRLZThe glutamic acid lowering properties of RLZ are ideally suited for the treatment of cocaineCOCaddictionand TRLZ is a major advance in delivering riluzole in vivo as validated in multiple in vivo studies in mouseratcynomolgous monkey and humansPhase I PKsafety and tolerability clinical trialTRLZ ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Molecular, cancer-specific, intraoperative imaging of breast surgical margin assessment

    SBC: AQD Life Sciences LLc            Topic: 396

    Molecularcancer specificintraoperative imaging of breast surgical marginTumor margin determination is critical for breast conserving surgeryCurrent re excision rates range fromtoIntraoperative tumor margin determination would enable complete tumor removal during the first surgery while the patient is still on the operating tableCurrentlythere is no method that is molecularly and cancer specificand ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of GPER agonists as Cancer Therapeutics

    SBC: Linnaeus Therapeutics LLC            Topic: 102

    Project summaryThis project is designed to evaluate a new class of anti cancer agents for treatment of invasive melanomapancreaslungand colon carcinomasThe study compounds are smallsynthetic molecules that have not previously been used in peopleand bind to a surface receptor on tumor cells that has not previously been targeted in cancerStrong preliminary results indicate that the study compounds p ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Graft-protective properties of LGM2605 in Lung Transplantation

    SBC: Lignamed, LLC            Topic: NHLBI

    LignaMedLLC is developing LGMa novel medical device that will be administered via an FDA approved ex vivo lung perfusion deviceEVLPto improve lung function parameters of ex vivo donor lungs in advance of transplant surgeryPer FDA device regulations LGMwill be fully flushed and cleared from the donor lung prior to transplantThe major challenge with lung transplantation is the oxidative damage that ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government